Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Luke Daniel Rothermel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5700-8028; OpenAlex author ID A5062156843. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2020: 2 papers · 2021: 5 papers · 2022: 7 papers · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 18

  1. A ketogenic diet sensitizes pancreatic cancer to glutamine metabolism inhibitors. Co-author DOI 10.1016/j.xcrm.2026.102770↗
  2. IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-1895↗
  3. An analysis of time to treatment in patients with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.03.011↗
  4. Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study. Co-author DOI 10.1245/s10434-023-14221-9↗
  5. Prodromal depression and anxiety are associated with worse treatment compliance and survival among patients with pancreatic cancer. Co-author DOI 10.1002/pon.5945↗
  6. Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. Co-author DOI 10.1016/j.amjsurg.2021.10.001↗
  7. Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreati… Co-author DOI 10.1016/j.hpb.2021.08.938↗
  8. Multimodal therapy with or without irreversible electroporation for unresectable locally advanced pancreatic adenocarcinoma: a systematic review and meta-analy… Co-author DOI 10.1016/j.hpb.2021.12.014↗
  9. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2022.07.007↗
  10. Time to Neoadjuvant Chemotherapy Initiation Is not Associated With Survival in Pancreatic Cancer. Co-author DOI 10.1016/j.jss.2022.03.013↗
  11. A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Co-author DOI 10.1016/j.surg.2021.10.023↗
  12. The importance of time-to-adjuvant treatment on survival with pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1002/cnr2.1390↗
  13. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodene… Co-author DOI 10.1016/j.surg.2020.12.003↗
  14. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1089/pancan.2021.0003↗
  15. The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center: A Retrospective Cohort Analysis. Co-author DOI 10.1097/sla.0000000000003706↗
  16. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagen… Co-author DOI 10.1177/00031348211038581↗
  17. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26196↗
  18. Case Report of Isolated Gastric Metastasis of Pancreatic Cancer From a Diagnostic Biopsy: Management of a Rare Oncologic Entity. Co-author DOI 10.1177/1073274820904042↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan Michael Winter · 16 shared papers, 2020–2026 · strength 2.41
  2. Jonathan J. Hue · 15 shared papers, 2021–2026 · strength 2.29
  3. John Brian Ammori · 13 shared papers, 2020–2023 · strength 1.90
  4. Lee Mayer Ocuin · 13 shared papers, 2020–2023 · strength 1.90
  5. Jeffrey M. Hardacre · 13 shared papers, 2020–2023 · strength 1.90
  6. Kavin Sugumar · 10 shared papers, 2021–2023 · strength 1.51
  7. Mohamedraed Elshami · 5 shared papers, 2022–2023 · strength 0.75
  8. David Lawrence Bajor · 5 shared papers, 2020–2022 · strength 0.65
  9. Sarah Coseo Markt · 4 shared papers, 2021–2022 · strength 0.56
  10. Ali Vaziri Gohar · 3 shared papers, 2022–2026 · strength 0.51
  11. Mehrdad Zarei · 3 shared papers, 2022–2026 · strength 0.51
  12. Omid Hajihassani · 3 shared papers, 2022–2026 · strength 0.51
  13. Shreya Gupta · 2 shared papers, 2023 · strength 0.36
  14. Mokenge Peter Malafa · 2 shared papers, 2020–2021 · strength 0.28
  15. Erryk Katayama · 2 shared papers, 2022 · strength 0.27
  16. Jennifer Anne Dorth · 2 shared papers, 2021–2022 · strength 0.26
  17. Moeez Ghani Rathore · 1 shared paper, 2026 · strength 0.19
  18. Joshua D. Rabinowitz · 1 shared paper, 2026 · strength 0.19
  19. Faith Nakazzi · 1 shared paper, 2024 · strength 0.18
  20. Akram S. Shalaby · 1 shared paper, 2024 · strength 0.18
  21. Jonathan Robert Brody · 1 shared paper, 2024 · strength 0.18
  22. Barbara Ann Centeno · 1 shared paper, 2020 · strength 0.16
  23. Hanna H. Kakish · 1 shared paper, 2022 · strength 0.14
  24. Richard S. Hoehn · 1 shared paper, 2022 · strength 0.14
  25. Nathaniel E Davis · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.